
















































































































???? ????? ???? ???? ????????? ??????? ??????? ????? ???????? ????? ???
????????????? ??? ???? ???? ????? ?????? ????? ?????????? ?????? ????
??????????????????? ??????? ??? ???????? ??????? ????????? ????? ??? ?
?????????????????? ?????? ??? ?????????????? ?????? ?????????
???????????? ???????????? ???????????? ???????? ?????? ?? ??????? ?? ?
??????????????????????????????????????????????????????????????
???????? ????? ????? ???? ??? ???? ???????? ???? ?????????? ????? ?? ?????
??????????????????????????????????????????????????????????? ??






??????????????????????? ?????? ????????????????????????????? ?????
??????????????????????????????????????????????????????????????
??? ????????? ???? ?????????? ??? ??????? ????? ???? ???? ??????
?????? ?????????? ?????????? ???????? ??????????? ??????? ? ????? ??
???? ??? ????????? ????? ????? ????????? ?????? ????? ????? ??
??????? ????? ???? ??? ??????? ???????????????????? ????
??????????????????????????????????????????????????????? ???
??????????????????????? ????????????????????? ?????? ??????????????????? ?????????








??? ??????????? ???? ?????? ??? ??????????????????? ?? ???? ???? ????
?????????????? ????????????????? ??????????????????????? ??????????
?????????????????????????????????????????????????????????? ?????
??????????????????????????????????????????????????????? ????????????







?????????? ??????? ???? ????? ?????? ????? ??????? ???? ?????? ? ??? ??????
???????? ??? ?????? ????? ???? ???????? ????? ??????? ?? ??? ????
?????? ??????????? ?????? ??? ???????????????? ??? ???? ????? ??? ??
???????????????????????????????????????????????????????????? ??
???????? ?? ??? ??????????????????? ???????????? ???????? ??? ????
?????????????????????????????????????????????????????????????
??????????????????? ???????? ???????? ??????? ??? ???? ????? ?????
???????????????????????????????????????????????????????????? ????





??? ?????????????? ??????? ????????? ??????????? ??? ?????? ???? ???? ??
????????????????????????????????????????????????????? ????????????????















??? ???? ???????????????????? ???? ??????????????????? ???????? ????????
????????????????????????????????????????????????????????????
?????????????????????????????????????? ?????????????????????????????
?????????????????? ????????????????????????????????????? ???????????? ?????
????? ??????????? ??????? ????? ????? ???? ???? ?? ???????????? ???????? ??? ?????
?????????????????????????????????????????????????????? ???????????????????????
?? ???? ?????? ????? ???????????? ??? ?????? ???? ??????? ??? ????
??????????????????????????????????????????????????????????? ?????
???????? ???? ??? ????????? ??????? ??????? ????? ????????????? ?? ????
??????? ??????? ???????????? ????? ??????? ???????? ???? ???????
?????????????? ??????? ??? ??????????? ??? ???? ??? ???? ?????? ?? ???? ???
???????????? ?????????????????????????? ???????????????????????????????
???????????? ???????????????????????????????????????????? ?????
?????????? ?????? ???? ???? ???? ???? ????? ?????? ????? ??? ????????
??????????? ???? ???? ????? ????? ????? ????? ????????????????? ????? ?????????
???? ???? ?????????????? ???? ??? ????? ??? ???????? ???????????
?????????????????????????????? ???????????????? ????????????????????????
???? ???? ??????????? ???????????????? ???????? ??? ?????? ????
??????????????? ???????????????????????????????????????????? ?
??????? ?????????? ?????? ? ????? ??????? ???? ????? ???? ????
???????????????? ???? ???? ?????????????? ???????? ??? ??? ????? ?? ????
?????????????
??? ????? ????????? ????? ?????? ????? ???? ??????????? ? ???? ?? ? ??? ???
??????????????????????????????????????????????????????????







????????? ???????? ???? ????? ???????????? ?? ?????????????? ??????? ?
????????????????????????????????????????????????????????? ??????????
??????????????????? ?????????? ?????????????????????? ???? ??????
???????????????????????????????????????????????????????????
???????????????? ??????? ??? ?????? ????? ??? ???? ??? ???????? ???? ??
???? ??????? ?? ??? ??????? ?? ???? ?????? ???????????? ??? ????? ??? ?? ??
?????????? ???? ???????? ?????????????? ???????? ???????? ?? ??? ?????
??????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????? ????????
??????????? ????????? ???? ????????? ??? ???????? ?? ???? ??? ???? ??????
???????????? ??????? ?????????? ???? ???? ??? ??? ??????????? ?? ?????
??????????????????????????????????????????????????????? ????????
??? ??????? ??? ?????? ??????? ??????? ??? ?????? ???????????? ?????
???????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ?????
???? ??????????????????? ????? ????????? ??? ?????????? ?????????? ?
????? ?????????? ??? ????????????? ?? ??? ???? ???????? ?????????? ? ??? ????
????????????????????????????????????????????????????? ?????????????
??????????????????????????????????????????????????????????








?????????????? ?????????????? ???????? ???? ?????? ????? ?? ??? ? ??????
????? ???????????? ??? ????????????? ?????????? ???? ??????????? ?? ?
???????????????? ???? ?????????? ???????? ?????? ?? ????? ????????? ??





????? ?????????????? ??? ???? ????????????? ???????? ???? ????? ?????
???? ?????????????? ??????????? ????????????? ???? ??????????? ?????
?????? ???? ???????????? ??? ????????????? ???????? ???? ?????????? ??
?????????????????????????????????????????????????????????? ?????????
??? ?????? ?????? ??? ???????? ??? ??????????????? ???????????
?????????????????????????????????
?????????????????????????????????????????????????????????????? ???
???????????? ??????????? ????????? ??? ?????? ????? ???? ???????? ??? ??
????????????????????????????????????????????????????????? ????????
????? ?????????????????????????????????????????????????????















??? ????? ??????????? ????? ?????????? ??? ???? ????? ??? ??????????
?????????? ??????? ??? ???????? ??? ??????? ????? ???? ???????? ???? ??
???????????????????????????????????????????????????????????
???? ???? ????????? ??????????? ????????? ???????? ??????? ????????? ??
???? ????????????? ????? ??? ???????????? ?????? ?? ??????? ??? ????
??????????????????????????????????
?????????????????????????????????????????????????????????? ??????





Procalcitonin-guided therapy in intensive care unit patients with 
severe sepsis and septic shock – a systematic review and meta-
analysis 
Anna Prkno1,2, Christina Wacker1,2, Frank M Brunkhorst2,3,†, Peter Schlattmann1,2,*,† 
 
Abstract 
Introduction: Procalcitonin (PCT) algorithms for antibiotic treatment decisions have been studied in 
adult patients from primary care, emergency department, and intensive care unit (ICU) settings, 
suggesting that procalcitonin-guided therapy may reduce antibiotic exposure without increasing the 
mortality rate. However, information on the efficacy and safety of this approach in the most vulnerable 
population of critically ill patients with severe sepsis and septic shock is missing. 
 
Method: Two reviewers independently performed a systematic search in PubMed, Embase, ISI Web 
of Knowledge, BioMed Central, ScienceDirect, Cochrane Central Register of Controlled Trials, 
http://www.ClinicalTrials.gov and http://www.ISRCTN.org. 
Eligible studies had to be randomized controlled clinical trials or cohort studies which compare 
procalcitonin-guided therapy with standard care in severe sepsis patients and report at least one of the 
following outcomes: hospital mortality, 28-day mortality, duration of antimicrobial therapy, length of 
stay in the intensive care unit or length of hospital stay. Disagreements about inclusion of studies and 
judgment of bias were solved by consensus. 
 
Results: Finally seven studies comprising a total of 1,075 patients with severe sepsis or septic shock 
were included in the meta-analysis. 
Both hospital mortality (RR [relative risk]: 0.91, 95%CI [confidence interval]: 0.61; 1.36) and 28-day 
mortality (RR: 1.02, 95%CI: 0.85; 1.23) were not different between procalcitonin-guided therapy and 
standard treatment groups. 
Duration of antimicrobial therapy was significantly reduced in favor of procalcitonin-guided therapy (HR 
[hazard ratio]: 1.27, 95%CI: 1.01; 1.53). Combined estimates of the length of stay in the ICU and in 
hospital did not differ between groups. 
 
Conclusion: Procalcitonin-guided therapy is a helpful approach to guide antibiotic therapy and 
surgical interventions without a beneficial effect on mortality. The major benefit of PCT-guided therapy 
consists of a shorter duration of antibiotic treatment compared to standard care. 
Trials are needed to investigate the effect of PCT-guided therapy on mortality, length of ICU and in-
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Introduction
Severe sepsis and septic shock are common diseases
in ICUs, with high mortality rates [1,2]. According to
more recent data from the Statistical Federal Office in
Germany, there were 88,000 patients with severe sep-
sis or septic shock in 2011 in German hospitals, with
associated hospital mortality rates of 43% for severe
sepsis and 60% for septic shock, respectively [3]. To
overcome this high mortality, an adequate antimicro-
bial therapy starting at an early stage is mandatory.
To guide such a therapy, the most promising parame-
ters appear to be plasma levels of procalcitonin (PCT)
[4]. Besides PCT, no other sepsis biomarker has achieved
universal use throughout different healthcare settings
in Germany and neighboring Europe in the last dec-
ade. High PCT concentrations are typically found in
bacterial infection, in contrast to lower levels in viral in-
fection and levels below 0.1 ng/mL in patients without
infection [5]. Furthermore, serum PCT concentrations
are positively correlated with the severity of infection.
Thus, adequate antibiotic treatment leads to decreasing
PCT levels [5].
Recent reviews focused on PCT-based algorithms in
patients with infections in general [6,7], respiratory tract
infections [8,9], or patients treated in the ICU [10-13].
These reviews focused on different patients in different
settings with different treatment algorithms. Most of
them included critically ill patients with different disease
severity ranging from suspected infection to pneumonia
or sepsis [10-13]. The others comprised even more pa-
tients of different settings: patients with various diseases
such as sepsis, bronchitis, and respiratory tract infection,
in various settings (primary care, emergency department,
ICU, and inpatient wards) were combined in one review
[6,7]. Two reviews focused only on patients with respira-
tory tract infection [8,9]. However there is no review ex-
clusively including the population of ICU patients with
severe sepsis or septic shock: both entities are hereinafter
collectively referred to severe sepsis. Our meta-analysis
addresses two essential research questions: 1) does a
PCT-guided strategy to determine the duration of anti-
microbial therapy reduce antibiotic use compared with a
strategy not based on PCT? 2) Does such a PCT-guided
strategy improve health outcomes compared with a strat-
egy not based on PCT? [14]. As evidence for the effect of
PCT-guided therapy in severe sepsis is missing, we inves-
tigated the effect of PCT-guided therapy compared to
standard care.
Materials and methods
The systematic review was performed following current
guidelines and is reported according to the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) statement [15,16].
Literature search and data extraction
Two reviewers (AP, CW) independently performed a sys-
tematic search in the databases Medline via PubMed,
Excerpta Medica database (Embase), ISI Web of Know-
ledge including the databases Web of Science, Journal
Citation Reports and Science Citation Index (SCI). Fur-
thermore, searches in BioMed Central, ScienceDirect
and the Cochrane Central Register of Controlled Trials
were continued. To identify unpublished or ongoing stud-
ies and to obtain the study protocols we searched two fur-
ther websites (http://www.ClinicalTrials.gov and http://
www.ISRCTN.org). The following keywords or medical
subject headings (MeSH) were used: “procalcitonin” or
“PCT” combined with “sepsis” or “SIRS” or “systemic in-
flammatory response syndrome” or “bacterial infection”.
All databases had been searched up to 14 June 2013.
All primary intervention studies were included that
compared PCT-guided therapy with standard care ac-
cording to current guidelines that met the following in-
clusion criteria: 1) studies that assessed the efficacy of a
treatment algorithm based on procalcitonin; 2) studies
that had a well-defined standard for the target condition
(severe sepsis), which included the use of definitions
according to the American College of Chest Physicians
(ACCP)/Society of Critical Care Medicine (SCCM) Con-
sensus Conference [17] and the German Sepsis Society
[18]; and 3) studies that provided sufficient information to
calculate the relative risk (RR) together with 95% CI or the
hazard ratio (HR) together with 95% CI respectively.
Eligible studies had to be randomized controlled clin-
ical trials (RCTs) or prospective cohort studies. Studies
dealing with neonates were excluded, because of consid-
erable differences in diagnosis, course and therapy of
sepsis compared to adults. The published language was
not restricted. Disagreements of judgment and inclusion
of studies were solved by consensus.
Data were extracted using a structured data collec-
tion sheet including the following items: authors and
year of study, design, setting, diagnosis, procalcitonin
test, randomization, number and characteristics of par-
ticipants, interventions, outcomes, duration, availabil-
ity of study protocol, and country. Primary outcomes
of this meta-analysis were 28-day mortality and hos-
pital mortality. Secondary outcomes were duration of
antimicrobial therapy, length of stay in the ICU and
length of stay in the hospital. If additional informa-
tion was needed, the authors of the studies were
contacted by Email. Eligible studies with insufficient
data for calculation or missing replies from the authors
were excluded.
Risk of bias
For assessing risk of bias, we applied the Cochrane
Collaboration tool for assessing risk of bias by judging
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seven items representing sources of risk of bias [19]. The
following items were evaluated: sequence generation, allo-
cation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
selective reporting, and other bias. The classification of the
assessment was: low risk of bias, high risk of bias, or uncer-
tain risk of bias. The assessment was done independently
by two reviewers (AP, CW). Disagreements were resolved
by consensus.
Statistical analysis
The statistical calculations were done with the freely
available software R [20] using the R package meta [21].
Results were presented graphically using forest plots. As a
meta-analysis is an observational study, the statistical ana-
lysis covered the investigation of bias and heterogeneity. A
formal analysis of publication bias was based on Egger’s
test [22]. For dichotomous outcomes (for example, hos-
pital mortality) RRs were calculated for every single study
by means of 2 × 2 contingency tables. The calculation of
combined estimates was performed using the Mantel-
Haenszel method. For continuous outcomes (for example,
length of antibiotic treatment) HRs based on the ex-
ponential distribution were calculated together with their
variances [23]. This approach was chosen because the ne-
cessary information for the calculation of standardized
mean differences was not available. Thus, the length of
stay and antibiotic therapy were modeled using the expo-
nential distribution. This approach was chosen rather
than the standardized differences because it can be used
if only the mean duration is reported in the respective
study. Summary estimates were obtained using the in-
verse variance method.
Heterogeneity was assessed using the Cochran Q-test
and the I2 measure [24]. The heterogeneity variance
tau2 was calculated using the moment estimator of
DerSimonian-Laird [25]. For all outcomes the fixed effect
model as well as the random effects model was applied.
Outliers and influential studies were investigated using
case-deletion techniques analysis in order to identify stud-
ies with great impact on the overall results.
Results
Literature search
We identified 9,071 records by searching the databases
PubMed, Embase, ISI Web of Knowledge, BioMed Cen-
tral, ScienceDirect and the Cochrane Central Register of
Controlled Trials. After removing 5,602 duplicates, the
titles and abstracts of the remaining 3,469 records were
screened. Therefore 3,360 records could be excluded. By
assessing the full-text articles of the remaining 109 re-
cords, 7 studies [26-32] fulfilled the inclusion criteria
and were thus eligible for our meta-analysis (Figure 1).
Furthermore, we identified 7 ongoing studies registered
at http://www.ClinicalTrials.gov that might deliver im-
portant results for future meta-analyses.
We excluded two studies due to insufficient informa-
tion and missing replies [33,34].
The study from Bagnenko et al. [34] was excluded be-
cause of missing data and deficits in quality: the inclu-
sion of patients was not clearly described, the exact
number of patients treated in each group was not given,
for hospital mortality only percentages without absolute
numbers were reported, and finally the treatment regi-
men for the control group was not specified. The au-
thors did not respond to clarify these questions. Another
study had to be excluded, because information of a sub-
group of 25 patients with sepsis was missing [33]. Again,
the authors did not respond to clarify these questions. In
particular we tried to obtain the data for all septic pa-
tients included in two trials [27,29]. In one case, further
information was provided [29], in another the authors
did not pass on any further information, so we could
only include the patients with septic shock from this
study [27].
Publication bias
As only seven studies were included in the meta-analysis,
assessment of publication bias using a funnel plot, fol-
lowed by a linear regression test of funnel plot asymmetry
(Egger’s test) [22], was not possible.
Study characteristics
All eligible studies were published in the English lan-
guage. Because no cohort study met the inclusion
criteria, the meta-analysis only consists of RCTs. All
studies were conducted in Europe between 2003 [32]
and 2009 [26]. Four studies were conducted in mixed
surgical/medical ICUs [26,27,29,30], and three studies
were conducted in surgical ICUs without medical patients
[28,31,32]. The number of included patients from each
study ranged from 27 [31] to 459 [29] with a total number
of 1,075 patients. In two studies the subgroup of septic
patients was included [27,29].
For PCT measurements three different PCT tests were
used: Brahms PCT Kryptor [26,27,29,30], Brahms PCT
LIA [28,31] and Brahms PCT-Q [32]. The main focus in
the PCT-guided therapy was on de-escalation in three
studies [28,30,31], on de-escalation as well as escalation
in two studies [26,27], and mainly on escalation in two
studies [29,32]. A summary of study characteristics and
treatment algorithms of the eligible studies is shown in
Tables 1 and 2.
Risk of bias
The overall risk of bias was moderate according to the
Cochrane Collaboration tool for assessing risk of bias of
all included studies. Two studies achieved low overall
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risk of bias [27,32], whereas the remaining studies had
moderate overall risk of bias [26,28-31]. Two items had low
risk of bias in all studies: “incomplete outcome data” and
“other bias”. Oftentimes the risk of bias remained unclear
due to insufficient information given in each study.
Figure 2 summarizes the risk of bias of included stud-
ies. Detailed information about risk of bias, support for
judgment of bias and graphically summarized informa-
tion on risk of bias are given in the online supplement
(Additional files 1 and 2).
Combined estimates
Primary outcomes
Hospital mortality in severe sepsis patients was reported
in four studies [26,28,30,31]. The combined estimate of the
RR based on the fixed-effect model for hospital mortality is
0.91 (95% CI: 0.61; 1.36) (Figure 3), with no differences be-
tween the PCT-guided therapy and standard-care group.
The test of heterogeneity showed no significant het-
erogeneity between these studies (Q = 0.66; df = 3; I2 = 0%;
tau2 = 0; P = 0.8835).
9071 of records identified through database searching
3469 records after duplicates removed
3360 records excluded
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Figure 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram. Study identification and selection
process. SIRS, systemic inflammatory response syndrome; ACCP, American College of Chest Physicians; SCCM, Society of Critical Care Medicine;
PCT, procalcitonin. *, available online at http://www.ClinicalTrials.gov.
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Table 1 Characteristics of included studies














Design RCT RCT RCT RCT RCT RCT RCT
Setting Surgical and medical ICU Surgical and medical ICU Surgical ICU Surgical and medical ICU Surgical and medical ICU Surgical ICU Surgical ICU
Condition Severe sepsis and septic
shock
Septic shock Severe sepsis Severe sepsis and septic
shock
Severe sepsis and septic
shock
Severe sepsis Severe sepsis
Total number of included
patients
61 267 110 459 79 27 72
Number of patients
PCT group/control group 31/30 138/129 (septic shock) 57/53 247/212 39/40 14/13 38/34
55/53 (positive blood culture)
Hospital mortality
Relative risk (95% CI) 0.68 (0.30; 1.55) NA 1.00 (0.53; 1.86) NA 1.03 (0.46; 2.31) 0.93 (0.23; 3.81) NA
Events PCT group/events control
group
7/10 15/14 9/9 3/3
28-day mortality
Relative risk (95% CI) NA 1.15 (0.81; 1.63) NA 1.02 (0.80; 1.30) 1.03 (0.43; 2.46) NA 0.69 (0.35; 1.36)
Events PCT group/events control
group
48/39 (septic shock) 90/76 8/8 10/13
Duration of antibiotic
treatment, days
PCT group/control group 5/5 (median) 9.8/12.8 (mean) (only positive
blood culture)
5.9/7.9 (mean) NA 6.0/9.5 (median) 6.6/8.3 (mean) NA
Length of ICU stay, days
PCT group/control group 22/23 (median) NA 15.5/17.7 (mean) 6.0/5.0 (median) 4.0/7.0 (median) 16.4/16.7 (mean) 16.1/19.4 (mean)
Length of hospital stay, days
PCT group/control group 27/33 (median) NA NA 23.0/22.0 (median) 17.0/23.5 (median) NA NA
SOFA score
PCT group/control group 9.5/10 (median) NA 6.7/7.0 (mean) NA 6.4/6.6 (mean) 7.3/8.3 (mean) 7.9/9.3 (mean)
8.5 to 11/8 to 11 (IQR) 3.68/3.62 (SD) 3.3/3.0 (SD) 3.5/4.2 (SD) 2.8/3.3 (SD)
Medical patients, %* 97% 89% 0% 59% NA 0% 0%
Subgroup of study No Yes No Yes No No No
Duration of study, months 36 12 15 29 15 7 29
Study protocol available Yes Yes Yes Yes Yes No No
Country France France Germany Denmark Switzerland Germany Czech Republic





















































Table 2 PCT assays and algorithms used for procalcitonin (PCT)-guided treatment in the included studies





Medical patients: Antibiotic treatment at the discretion of
the patient’s physician
PCT <0.25 ng/mL: antibiotics not initiated or stopped
PCT≥ 0.25 and < 0.5 ng/mL: Antibiotics strongly discouraged
PCT ≥0.5 and <5 ng/mL: antibiotics recommended
PCT ≥5 ng/mL: antibiotics strongly recommended
Surgical patients:
PCT <4 ng/mL: antibiotics not initiated or stopped
PCT ≥4 and <9 ng/mL: antibiotics recommended





Guidelines for starting of antibiotics: Treatment according to international and
local guidelines
PCT <0.25 ng/mL: antibiotics strongly discouraged
PCT ≥0.25 and <0.5 ng/mL: antibiotics discouraged
PCT ≥0.5 and <1 ng/mL: antibiotics encouraged
PCT ≥1 ng/mL: antibiotics strongly encouraged
Guidelines for continuing or stopping of antibiotics:
PCT <0.25 ng/mL: stopping of antibiotics strongly encouraged.
Decrease by ≥80% from peak concentration, or concentration
≥0.25 and <0.5 ng/mL: stopping of antibiotics encouraged
Decrease by <80% from peak concentration and concentration
≥0.5 ng/mL: continuing of antibiotics encouraged
Increase of concentration compared with peak concentration






PCT < 1 ng/mL: Antibiotics discontinued. Antibiotic treatment according to standard
regimen over 8 days
PCT >1 ng/mL and dropped to 25 to 35% of the initial value
over 3 days: antibiotics discontinued





Single baseline measurement of PCT ≥1.00 ng/mL or PCT
≥1.00 ng/mL and not decreased at least 10% from the
previous day:
Antibiotic treatment according to current
guidelines
1) increasing the antimicrobial spectrum covered
2) intensifying the diagnostic effort to find uncontrolled
sources of infection





Patients with PCT <1 ng/mL re-evaluated at day 3: antibiotics
discontinued if PCT <0.1 ng/mL
Antibiotic treatment based on empirical
rules
Patients with PCT ≥1 ng/mL re-evaluated at day 5: antibiotics
discontinued if PCT dropped >90% from the baseline peak





PCT <1 ng/mL and clinical signs of infection improved:
antibiotics discontinued
Antibiotic treatment according to clinical
signs and empiric rules
PCT dropped to <35% of the initial concentration within




Brahms PCT-Q PCT >2 ng/mL: change of antibiotics and catheters Treatment according to contemporary
treatment protocol of the institute
PCT ≤2 ng/mL: ultrasonography and/or computer tomography
followed by repeated surgical treatment if localized infection
was confirmed
PCT, procalcitonin.
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The 28-day mortality was covered in four studies
[27,29,30,32]. The combined estimate of the RR based
on the fixed-effect model for 28-day mortality is 1.02
(95% CI: 0.85; 1.23) (Figure 4), again, with no difference
between the PCT-guided therapy and standard care
group. The test of heterogeneity showed no significant
heterogeneity between these studies (Q = 1.74; df = 3;
I2 = 0%; tau2 = 0; P = 0.6287).
The influential analysis using both the fixed-effect
model and the random-effects model showed that no
study had great impact on the overall results of hospital
mortality and 28-day mortality, respectively.
Secondary outcomes
The duration of antimicrobial therapy in severe sepsis
patients was documented in five studies [26-28,30,31]. In
one study we could only include the subgroup of septic
patients with positive blood cultures for assessment of
this outcome [27]. The combined estimate for the dur-
ation of antimicrobial therapy assessed as the HR and
based on the fixed-effect model amounted to 1.27 (95%
CI: 1.01; 1.53) (Figure 5). These results indicate a signifi-
cantly shorter median duration of antimicrobial therapy
with PCT-guided therapy compared to standard ther-
apy. No significant heterogeneity could be detected
between these studies (Q = 1.92; df = 4; I2 = 0%; tau2 = 0;
P = 0.7499).
The length of stay in the ICU (ICU-LOS) was docu-
mented in five studies [26,28,30-32]. Additionally, infor-
mation on ICU-LOS for the subgroup of patients with
severe sepsis of the study from Jensen et al. [29] was
available by correspondence (median ICU-LOS of 6 days
in the PCT group versus 5 days in the control group).
The combined estimate for ICU-LOS assessed as the HR
and based on the fixed-effect model is 0.93 (95% CI:
0.80; 1.06) (Figure 6). No significant heterogeneity was
detected between these studies (Q = 7.98; df = 5; I2 = 37.3%;
tau2 = 0.0227; P = 0.1575).
The length of hospital stay was reported in two studies
[26,30]. In addition we obtained the median hospital stay
for the subgroup of patients with severe sepsis of the
study from Jensen et al. [29] by correspondence with
the author (23 days in the PCT group versus 22 days in the
control group). The combined estimate assessed by the
HR and fixed-effect model amounted 1.00 (95% CI: 0.84;
1.17) (Figure 7). No significant heterogeneity was de-
tected between these studies (Q = 2.22; df = 2; I2 = 10%;






































































































































































Figure 2 Risk of bias summary. Cochrane Collaboration tool for
assessing risk of bias. Review authors’ judgments about each risk of
bias item for each included study. +, low risk of bias; −, high risk of
bias; ?, unclear risk of bias.
Figure 3 Forest plot - hospital mortality. The forest plot represents the relative risk (RR) together with the 95% CI comparing patients treated
in the procalcitonin (PCT) and the control groups (Control). Events, number of deceased patients in group; Experimental, PCT group; Total,
number of all patients in group; W, weight of individual studies (in fixed- and random-effects model).
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The influential analysis using the fixed-effect model
showed no predominant influence on the combined HR
of duration of antimicrobial therapy in any study. As
shown in the influential analyses based on the fixed-
effect model, the study from Jensen et al. had great in-
fluence on the combined estimates of ICU-LOS and
length of hospital stay, respectively. When omitting this
study, the results show a trend towards shorter ICU-
LOS (HR: 1.19; 95% CI: 0.93; 1.44) and hospital stay
(HR: 1.30; 95% CI: 0.87; 1.74) with PCT-guided therapy.
We did not detect significant heterogeneity among
these studies and therefore did not perform a meta-
regression analysis. Furthermore, the data basis for a
meta-regression is rather small.
Discussion
Our meta-analysis aimed to investigate the impact of a
PCT-guided therapy compared to standard treatment
administered to severe sepsis patients treated in an ICU.
Contrary to previous reviews that analyzed patients in
various settings with different disease severities, we fo-
cused on patients with severe sepsis, a population in
which clinical decision-making to stop antibiotic treat-
ment is challenging. In view of the high mortality rate in
severe sepsis, clinicians believe themselves to “be on the
safer side” with more prolonged courses of antimicrobial
treatment. Current evidence to limit duration of anti-
biotic treatment to 7 to 10 days is rather low and has
been included only as a grade-2C recommendation in
the recent guidelines of the Surviving Sepsis Campaign
[35], in which the authors state that “decisions to con-
tinue, narrow, or stop antimicrobial therapy must be
made on the basis of clinician judgment and clinical infor-
mation”. Variance of treatment regimens in the control
groups of our meta-analysis might therefore reflect the
current way of treatment of patients with severe sepsis.
Our findings do not show a significant difference be-
tween a PCT-guided therapy and standard care treatment
regarding 28-day or hospital mortality, respectively. Fur-
thermore, length of stay in the ICU and in-hospital stay
were not different between both groups. However, we
found a significant reduction of the length of antibiotic
therapy in favor of a PCT-guided therapy strategy. Our
calculations, based on the exponential model, indicate a
median length of antibiotic treatment of 6 days in the
PCT-guided group compared to 8 days in the control
group, resulting in a median reduction of approxi-
mately 2 days. A reduction of antimicrobial therapy using
Figure 4 Forest plot - 28-day mortality. The forest plot represents the relative risk (RR) together with the 95% CI comparing patients treated in
the procalcitonin (PCT) and the control groups (Control). Events, number of deceased patients in group; Experimental, PCT group; Total, number
of all patients in group; W, weight of individual studies (in fixed- and random-effects model).
Figure 5 Forest plot - duration of antimicrobial therapy. The forest plot represents the hazard ratios (HRs) together with the 95% CIs
comparing patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and
random-effects model).
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biomarkers for clinical decision-making may have certain
advantages, as antimicrobial resistance becomes more
prevalent by using prolonged courses of broad-spectrum
antimicrobial agents for treatment of severe sepsis patients
[36,37]. Moreover, antibiotic consumption and acquired
antimicrobial resistance had been shown to be associ-
ated with increased mortality, morbidity, length of hos-
pitalization, and health care costs [38,39].
Currently, no treatment algorithms for guidance of
severe sepsis treatment using PCT levels are well estab-
lished in this high-risk population. To establish a PCT-
guided treatment algorithm in severe sepsis patients, it
is important to distinguish between escalation and de-
escalation of therapeutic interventions. Reliable cut-off
values of PCT levels to guide therapeutic decisions need
to be defined in future studies, since treatment algo-
rithms varied substantially between the studies included
in our systematic review. For instance, Annane et al. and
Bouadma et al. [26,27] encouraged a prolongation of
antibiotic treatment if PCT levels were above 0.5 ng/mL,
and discouraged antibiotic treatment if levels dropped
below 0.5 ng/mL. Furthermore, Annane et al. distinguished
between medical and surgical patients. In surgical patients
a different algorithm was applied with a recommendation
to stop antibiotics when PCT levels were below 4 ng/mL.
Bouadma et al. recommended stopping antibiotics at PCT
levels below 0.25 ng/mL. If PCT levels were between
0.5 ng/mL and 0.25 ng/mL, antibiotics were stopped if
there was a decrease of at least 80% of the peak concentra-
tion of PCT levels. Four studies recommended a PCT level
of 1.0 ng/mL as the cutoff [28-31]. Hochreiter et al. and
Schroeder et al. recommended discontinuing antibiotics if
PCT was below 1.0 ng/mL. Both recommended to dis-
continue antibiotics if PCT levels dropped by 35% of
the initial level within 3 days. Nobre et al. recommended
discontinuing antibiotics in patients with PCT levels below
0.1 ng/mL after 3 days. In patients with PCT levels above
1.0 ng/mL antibiotics were discontinued if PCT levels
dropped more than 90% from the baseline peak level or if
PCT levels were below 0.25 ng/mL after 5 days.
In contrast to all other studies, Jensen et al. tested a
rigorous escalation strategy [29]. In the case of PCT levels
above 1.0 ng/mL an intensified antibiotic treatment strat-
egy was recommended. De-escalation was only possible if
Figure 6 Forest plot - length of stay in the ICU. The forest plot represents the hazard ratios (HRs) together with the 95% CIs comparing
patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and
random-effects model).
Figure 7 Forest plot - length of stay in the hospital. The forest plot represents the hazard ratios (HRs) together with the 95% CIs comparing
patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and
random-effects model).
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PCT levels dropped below 1.0 ng/mL for at least 3 days.
This treatment algorithm led to a prolonged length of stay
in the ICU and substantially higher use of broad-spectrum
antimicrobials. A different cut-off level of 2.0 ng/mL was
used by Svoboda et al. in surgical patients [32].
This meta-analysis has several limitations. First, stud-
ies included in our meta-analysis varied substantially in
study design and objectives. Two studies provided rules
for starting or continuing as well as discontinuing anti-
biotic treatment [26,27]. Three studies focused on de-
escalation of antibiotic therapy [28,30,31], whereas two
studies placed the focus on escalation of antibiotic treat-
ment and diagnostic efforts [29,32] and surgical treatment
[32]. Second, a limited number of patients is included,
third, a combined analysis of medical and surgical patients
is problematic, since there are substantial differences in
outcomes regarding surgical patients, where surgical
source-control measures play a dominant role.
In order to explore knowledge on a PCT-guided treat-
ment in severe sepsis patients in more detail, we await
the results of seven ongoing studies registered at http://
www.ClinicalTrials.gov that might deliver important re-
sults for future systematic reviews.
Conclusion
An approach along a biomarker-guided treatment algo-
rithm using procalcitonin levels may be helpful to guide
antimicrobial treatment in severe sepsis patients, treated
in ICUs and reduces the duration of antimicrobial therapy
without an obvious increase in mortality. However, more
research is urgently needed to investigate the safety and ef-
fectiveness in subgroups of surgical and medical severe
sepsis patients, treated in ICUs. Most importantly, treat-
ment algorithms differ substantially and have to be clarified
in future studies.
Key messages
 A PCT-guided treatment reduces the duration of
antimicrobial therapy in severe sepsis patients,
without increasing 28-day and in-hospital mortality
rates
 Recommendations for PCT-guided treatment
algorithms for treatment of severe sepsis patients
differ substantially among published studies
 Future studies have to show which PCT-guided
treatment algorithms could be recommended in se-
vere sepsis patients
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